<![CDATA[Genovis AB: Half-Yearly Report January-June 2023]]>Genovis AB: Half-Yearly Report January-June 2023

https://mb.cision.com/Main/1712/3820614/2247306.pdf

Link Preview Image
Half-Yearly Report January-June 2023

Continued strong growth in both enzyme and antibody business  April – June 2023 · Net sales

favicon

News Powered by Cision (news.cision.com)

Continued strong growth in both enzyme and antibody business

January - June 2023

Net sales totaled SEK 100,739 (53,667) thousand, with a growth rate of 88%. Growth is 76%, adjusted for currency effects. Organic growth adjusted for license revenues in the first quarter from Selecta Biosciences is 41%, and 30% when also adjusted for currency effects .....

Rigtigt godt regnskab fra Genovis.

Luk i kurs 49,15 & +13,12% 🙂

]]>https://dev.proinvestor.com/forum/topic/445506/genovis-ab-half-yearly-report-january-june-2023RSS for NodeTue, 23 Jun 2026 03:54:26 GMTThu, 24 Aug 2023 13:31:27 GMT60<![CDATA[Reply to Genovis AB: Half-Yearly Report January-June 2023 on Sat, 26 Aug 2023 17:28:02 GMT]]>Ja man kan vil ikke klage over dette flotte regnskab. Fremtiden ser lovende ud?. Haft aktien siden 2007.

]]>https://dev.proinvestor.com/forum/post/9484255https://dev.proinvestor.com/forum/post/9484255Sat, 26 Aug 2023 17:28:02 GMT